Dr. med. Thomas Mertenskoetter

 

Since December 2010

T.O.M. Life Science Consulting (T.O.M. LSC)
Thomas Mertenskoetter & Associates
Director
We at T.O.M. LSC support the pharmaceutical industry and global health field advancing their response to communicable diseases.

Jan. 2008 to Nov. 2010

International Partnership for Microbicides (HIV prevention)
Executive Director External Relations Europe

  • Leading IPM’s Resource Development engagement in Europe and Global Access Working Group
  • Scientific representation of IPM in Europe and collaboration with IPM’s European donors and Civil Society partners
  • Cooperation with industry partners, clinical and academic collaborators

Jan. 2002 to Jun. 2007

Gilead Sciences Germany
Director Medical Affairs

  • Leading medical/clinical department with 8 FTEs and member of leadership team
  • Responsible for development and coordination of scientific and medical marketing strategy of the portfolio in the fields of HIV, HBV, and fungal infection
  • Responsible for design, development and implementation of local HIV and Hepatitis clinical development plan and medical support of global clinical R&D
  • Responsible for implementation of scientific collaborations and setup of scientific HIV and Hepatitis advisory boards
  • Supervision of Medical Information function and “Qualified scientific person responsible” according German drug law

Feb. – Oct. 2003

Gilead Sciences Germany
Interim Acting General Manager

  • Leading German management team and business operations during interim period
  • Development and implementation of business turnaround-plan
  • Member of European management team

Jan. 1999 – Dec. 2001

GlaxoSmithKline, HIV R&D, Greenford, U.K.
Global Clinical Development and Product Strategy
Director Medical Communication Strategy

  • Member of international product development team for HIV protease inhibitor Agenerase and for anti-Malaria fixed dose combination Malarone
  • Development and execution of scientific communications and industry symposia at international HIV conferences and member of international clinical review team for local phase IIIB/IV HIV study proposals
  • Co-chair international GSK project team on observational database in HIV and scientific collaboration with external observational databases and head of International Annual GSK sponsored HIV Cohorts Workshop
  • Representation of GSK in international scientific collaboration (Oversight Committee for evaluation of metabolic consequences of HAART) with academia, industry, EMEA, FDA and community

Jul. 1997 – Dec. 1998

Glaxo Wellcome Germany, Medical Department
Medical Advisor Antibiotics, HIV, Hepatitis and Malaria

Residency:

1994 – 1997

Bernhard-Nocht-Institute for Tropical Medicine, in- and outpatient clinic
Physician and Regional Co-ordinator of the German AIDS Study Group (GASG)

1992 – 1993

University Hospital Hamburg-Eppendorf, HIV outpatient clinic of the medical department
Physician

Further Education:

1993 Board-certified physician
1992 Course in tropical medicine at the Bernhard-Nocht-Institute, Hamburg
1985–92 Medical studies at the University of Hamburg